Biogen Announces Changes to Its Board of Directors
- Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023, to Give All Stockholders Sufficient Time to Review and Vote on Proposed Slate
CAMBRIDGE, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced several changes to its Board of Directors today. The changes will refresh the composition of the Board and follow the Board’s continual interaction with company stockholders to solicit their perspective on a range of issues around the company’s performance and strategy.
Directors Alexander J. Denner, Ph.D., William D. Jones and Richard C. Mulligan, Ph.D., will no longer stand for re-election and Biogen announced the nomination of Susan Langer who will stand for election to the company’s board of directors at its annual meeting of stockholders. As previously announced, Board Chair Stelios Papadopoulos will step down from the Board after the Annual Meeting. He will be replaced as Board Chair by Caroline Dorsa.
In order to give stockholders sufficient time to review the changes, including Ms. Langer’s nomination, prior to voting, the Board will convene and then adjourn its Annual Meeting of Stockholders scheduled on June 14, 2023, and then reconvene on Monday, June 26, 2023.
“Today’s announcement is the culmination of an extensive shareholder engagement process and adds additional skills and experience from Ms. Langer, a highly qualified director who can help support Biogen’s ambitious growth plans,” said Ms. Dorsa.
“I want to thank Stelios, Alex, William, and Richard. They have made valuable contributions to our Board and Company as we delivered significant therapeutic breakthroughs and navigated numerous challenges. Their steady leadership, thoughtful counsel and dedication to Biogen’s innovative spirit leave a legacy on which we will continue to build.”
“This is an important time for Biogen as we are working to put the company back on a sustainable growth path to deliver enhanced value for our patients, employees and shareholders,” said Christopher A. Viehbacher, Biogen’s President and Chief Executive Officer. “I am looking forward to working alongside Caroline as chair and the entire Board and management team to meet that goal and deliver on this company’s full capabilities.”
Ms. Langer brings healthcare and biotech operational and strategy experience to the Board. She is President of Souffle Therapeutics. Previously, Ms. Langer was founding President of Kojin Therapeutics as well as founding Chief Business Officer of Paratus Sciences. Prior to that, Ms. Langer worked for Biogen in roles of increasing responsibility, including as Head of Corporate Strategy where she led the strategy and execution of more than a dozen corporate transactions as well as company-wide initiatives. She also serves on the Board of NextRNA Therapeutics. Ms. Langer has also previously served as Venture Partner at Old Silver VC and Managing Partner at Guava Partners. She received a BA from Cornell University.
About Biogen
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.
We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business, pipeline programs and clinical development programs. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “potential,” “possible,” “prospect,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our dependence on sales from our products; uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; failure to compete effectively due to significant product competition in the markets for our products; failure to successfully execute or realize the anticipated benefits of our strategic and growth initiatives; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; our dependence on collaborators, joint venture partners, and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; the potential impact of the conflict in Ukraine; risks associated with current and potential future healthcare reforms; risks related to commercialization of biosimilars; failure to obtain, protect, and enforce our data, intellectual property, and other proprietary rights and the risks and uncertainties relating to intellectual property claims and challenges; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; risks relating to technology failures or breaches; problems with our manufacturing processes; risks relating to management and personnel changes, including attracting and retaining personnel; failure to comply with legal and regulatory requirements; the risks of doing business internationally, including currency exchange rate fluctuations; risks relating to investment in our manufacturing capacity; the direct and indirect impacts of the ongoing COVID-19 pandemic on our business; risks relating to the distribution and sale by third parties of counterfeit or unfit versions of our products; risks relating to the use of social media for our business; results of operations, and financial condition; fluctuations in our operating results; risks related to investment in properties; the market, interest, and credit risks associated with our investment portfolio; risks relating to share repurchase programs; risks relating to access to capital and credit markets; risks related to indebtedness; change in control provisions in certain of our collaboration agreements; fluctuations in our effective tax rate; environmental risks; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission. These statements speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements.
| MEDIA CONTACT(S): Biogen Jack Cox + 1 781 464 3260 public.affairs@biogen.com | INVESTOR CONTACT(S): Biogen Chuck Triano +1 781 464 2442 IR@biogen.com |
